Express Pharma

Number of IO trials in China surge by more than 50 per cent in 2016 and 2017

1

GlobalData identified 819 clinical trials that have been initiated in the last 10 years (2008-17) to investigate I/O drug candidates

In recent years, China increased its focus on the clinical trial investigation of immuno-oncology (I/O) drug candidates. The number of clinical trials recorded a compound annual growth rate (CAGR) of ~34 per cent since 2008, according to leading data and analytics company GlobalData.

GlobalData identified 819 clinical trials that have been initiated in the last 10 years (2008-17) to investigate I/O drug candidates. More than half (n=464) of these trials were initiated in 2016 and 2017. Phase II clinical trials accounted for nearly 28 per cent of the total clinical trials conducted in China, followed by Phase I (24 per cent) and Phase I/II (24 per cent).

In the I/O clinical trials, 67 per cent of the trials were in progress, 24 per cent were completed and 5 per cent were planned. Out of these completed trials, 51 per cent were reported with results. FUDA Cancer Hospital is the major non-industry player investigating I/O drug candidates in China. The other top non-industry sponsors were China PLA General Hospital, Sun Yat-sen University.

Jiangsu Chia-tai Tianqing Pharmaceutical Co emerged as the top industry sponsor. Other top industry sponsors were Bristol-Myers Squibb Co, F Hoffmann-La Roche and Novartis.

The major indications under investigation include Non-Small Cell Lung Cancer, Solid Tumor, Hepatocellular Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), and breast cancer, etc. The top five I/O drug candidates investigated in the clinical trials that were started in recent years (2016-17) include Cellular Immunotherapy for Oncology, tucidinostat, SHR-1210, nivolumab and anlotinib hydrochloride.

Comments are closed.